Approval Date: Jun 2024
Indicated for the treatment of erectile dysfunction
Approval Date: Jun 2024
A biosimilar to Stelara; indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis
Approval Date: Jun 2024
A new chewable tablet indicated for the treatment of erectile dysfunction, and the signs and symptoms of benign prostatic hyperplasia
Approval Date: May 2024
Indicated for the treatment of HIV-1 infection, in combination with other antiretroviral agents
Approval Date: May 2024
Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure
Approval Date: Apr 2024
Indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression
Approval Date: Apr 2024
A biosimilar of Stelara®, this drug is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis
Approval Date: Mar 2024
A long-acting, atypical antipsychotic indicated for the treatment of schizophrenia
Approval Date: Mar 2024
A first-in-class biologic indicated for the treatment of pulmonary arterial hypertension to increase exercise capacity and reduce the risk of clinical worsening events
Approval Date: Mar 2024
Indicated for the treatment of pulmonary arterial hypertension, both in patients who are treatment naïve or who are already on an ERA, PDE5 inhibitor or both